Towia Libermann, PhD
A proof-of-concept study has found that a panel of six serum proteins can help physicians distinguish simple steatosis from more advanced liver disease, which may be immediately useful in clinical trials.
Researchers led by Towia Libermann, PhD, of Beth Israel Deaconess Medical Center, in Boston, showed that the noninvasive test, called the NASH-dx, can differentiate between simple steatosis and non-alcoholic steatohepatitis with an accuracy of 98%. The new panel also